Applied Therapeutics, Inc. - APLT EV/Sales Multiple

Public company logo of Applied Therapeutics Inc. (APLT)

Applied Therapeutics develops drugs for rare metabolic pathologies, betting on the high margins of orphan products. This price-to-sales ratio chart illustrates the asset's dynamics, where 5410.00 serves as the current parameter value. The business relies on sales of medications for the treatment of galactosemia, however, a critical dependence on FDA verdicts creates binary risks amid borderline liquidity levels.

Applied Therapeutics, Inc. - APLT Enterprise Value-to-Revenue Ratio (period 11/23/2025 - 02/16/2026)

appliedtherapeutics.com - analytical breakdowns and key metrics (APLT)

Initial company analysis:appliedtherapeutics.com
Mass-produced product of Applied Therapeutics

Applied Therapeutics possesses monopoly potential due to the market launch of unique drugs for the treatment of rare metabolic diseases. An analysis of the current EV/Sales ratio allows for the valuation of the entire business relative to revenue, excluding the impact of debt load, which helps investors determine the fair price of the asset and identify either the company's undervaluation or risks of structural decline.